



Multiple**MS**

# NEWSLETTER

## CURRENT NEWS




### Retrospective study:

We are now well on our way to uploading genetic data in the central database.

The accompanying clinical data is being extracted from the individual databases and patient journals and will be added to the genetic data.

All data is treated anonymously to adhere to the current ethical rules and regulations.

### Prospective study:



By May 14<sup>th</sup>, 41 newly diagnosed MS patients from eight MultipleMS centres have been enrolled in the prospective study. From these patients we have collected clinical data, as well as biomaterial samples such as immune cells, DNA, RNA, serum and plasma.

Our goal is to recruit 500 newly diagnosed MS patients, which we will follow over at least three years.

### Contact information:

- Official webpage: <http://www.multiplems.eu>
- Stakeholder registration: <http://www.multiplems.eu/Newsletters/>
- MultipleMS on facebook: [www.facebook.com/multipleMS](http://www.facebook.com/multipleMS)
- Twitter: @MultipleMS\_EU



## SUMMER 2018

### The MultipleMS General Assembly and Stakeholder workshop



The annual MultipleMS general assembly was held at the Holton London Heathrow Airport Hotel May 15<sup>th</sup> 2018, followed by our first Stakeholder workshop on May 16<sup>th</sup>.

Stakeholders representing patient organisations, pharmaceutical companies and research associations were gathered with MultipleMS consortium members to discuss the project and the stakeholder`s expectations and needs.

The following Stakeholders were represented: Biogen, DeCode,ECTRIMS, European Association of Neurology, Italian MS Association, MAGNIMS, Merck, MS DataConnect, MS International Federation, Novartis, Olink, RIMS, The Accelerated Cure Project/ iConquerMS, The European Brain Council, The European MS platform, The International MS microbiome study, the MS Society of Norway, The Stockholm County Council.